| abstract |
The present invention relates to a pharmaceutical use of polygamma glutamic acid used in the prevention or treatment of Th17 mediated diseases, and provides a pharmaceutical composition for the prevention or treatment of Th17 mediated diseases comprising polygamma glutamic acid as an active ingredient. The pharmaceutical composition of the present invention has the effect of inhibiting the differentiation of Th17 cells and promoting the differentiation of T reg cells, such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease ( It can be usefully used for the prevention and treatment of Th17 mediated diseases such as Crohn's disease. |